After flopping a phase 3 trial in hospitalized COVID-19 patients, Molecular Partners’ antiviral ensovibep has scored in a new phase 2 study, reducing viral load and cutting the risk of…

Several drugs entering the market or launching key indications in 2022 are predicted to achieve blockbuster status by 2026. Source: Drug Industry Daily

Bayer and Mammoth Biosciences have announced a deal in which Bayer will shell out $40 million now and potentially up to $1 billion over time for the use of Mammoth’s…

In its first-ever FDA approval, Switzerland’s Idorsia has snagged the regulatory green light for Quviviq (daridorexant), a potential blockbuster treatment for adults with insomnia. Source: Drug Industry Daily

Pfizer has partnered with Beam Therapeutics to develop messenger RNA (mRNA)-based therapies for rare genetic diseases — a move to expand its portfolio of mRNA technology used to produce its…

The FDA will soon decide whether Eli Lilly’s and Innovent Biologics’ immunotherapy sintilimab can get the go-ahead in the U.S. for the treatment of lung cancer. Source: Drug Industry Daily

Tirzepatide, Eli Lilly’s potential dual-molecule blockbuster for type 2 diabetes (T2D), should be priced at $5,500 to $7,500 per year to be a cost-effective therapeutic option, according to the Institute…

France’s Sanofi and UK-based Exscientia have struck a deal potentially worth $5.2 billion to develop up to 15 new therapies for cancer and immunology indications using Exscientia’s artificial intelligence-based drug…

A federal judge in Texas has ruled that the FDA must by the end of this month make public 12,000 pages of the data it used to make decisions about…

A federal judge has thrown out Amarin’s complaint against Hikma Pharmaceuticals over the latter’s alleged patent infringement by its generic version of Vascepa (icosapent ethyl). Source: Drug Industry Daily